“Organize your Events at OMICS Group Conferences”

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to symposia@omicsonline.org

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: cancerscience-2013@omicsonline.net
09:00-09:05  Introduction
09:05-09:30  Stewart Sell
            Wadsworth Center, USA
09:30-09:55  Michael Retsky
            Harvard School of Public Health, USA
09:55-10:20  Jimmy T. Efird
            Brody School of Medicine, USA

Track 1: Cancer Therapy and Clinical Cancer Research
Session Chair: Stewart Sell, Wadsworth Center, USA
Session Co-Chair: Su-shing Chen, University of Florida, USA

10:35-10:55  A gene signature that predicts deficiency of homologous recombination DNA repair in cancer
            Shiaw-Yih (Phoebus) Lin, MD Anderson Cancer Center, USA
            Rationale-driven identification of novel gemcitabine sensitivity genes as biomarkers of outcome in pancreatic cancer patients by exploiting the replication stress response
            David S. Yu, Emory University School of Medicine, USA
11:15-11:35  Targeting cellular survival responses to replication stress in cancer
            Guang Peng, MD Anderson Cancer Center, USA
            A novel role of 53BP1 in alternative non-homologous end joining
            Junran Zhang, Case Western Reserve University, USA
11:55-12:15  Regulation of stemness gene expression and tumorigenicity by an endogenous matrix metalloproteinase inhibitor RECK
            Wen-Chun Hung, National Institute of Cancer Research, Taiwan
12:15-12:35  Role of the TMPRSS2-ERG gene fusion and autophagy in DNA damage and repair of prostate cancer
            Alex Bishop, University of Texas Health Science Center, USA
12:35-12:55  Identifying the molecular basis for PARP1 inhibition sensitivity in Ewing's sarcoma, potential for stratifying patients during clinical trials and implications for breast and ovarian cancer
            Alex Bishop, University of Texas Health Science Center, USA
13:35-13:55  A critical role of the SUMO pathway in KRAS-driven oncogenesis
            Ji Luo, National Cancer Institute, USA
15:15-15:30  Cancer Applications of Multistage Nanovector Systems Based on Microfabricated Porous Silicon Particles
            Biana Godin-Vilentchouk, Houston Methodist Research Institute, USA
15:35-15:55  Recombinant immunotoxin targeting cancer specific surface antigen for cancer therapy
            Tapan K Bera, National Cancer Institute, USA
16:30-16:50  Nutritional aspects in the treatment of head neck cancer patients
            Jens Buentzel, Suedharz Klinikum Nordhausen, Germany
            A synergistic strategy of cancer therapies: The scientific foundations and clinical opportunities
            Su-shing Chen, University of Florida, USA
16:50-17:10  Targeting early B-cell receptor signaling inducements and apoptosis in leukemic mantle cell lymphoma
            Mahand-Akki Bokhliar, University of Paris, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30-17:50</td>
<td>A pre-clinical breast cancer stem cell model based on MMTV-PyMT mice for testing nanoparticle directed therapy</td>
<td>Stewart Sell, Wadsworth Center, USA</td>
<td></td>
</tr>
<tr>
<td>17:50-18:10</td>
<td>Prevention of fibroblast senescence by hyaluronic acid and clinical application to chemoradiation-induced oral mucositis</td>
<td>Nicola Cirillo, The University of Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td>18:10-18:30</td>
<td>The Rediscovery of UPI-928</td>
<td>John Rothman, Update Pharma Inc., USA</td>
<td></td>
</tr>
<tr>
<td>18:30-18:50</td>
<td>Alteration of B-Cell Receptor (BCR) signaling in B-cell lymphomas: New therapeutic targets for lymphoma treatment</td>
<td>Dominique Ledoux, University of Paris, France</td>
<td></td>
</tr>
<tr>
<td>18:50-19:10</td>
<td>Mucoadhesive Brazilian propolis gel for prevention of radiation-induced oral mucositis</td>
<td>Vagner Rodrigues Santos, Universidade Federal de Minas Gerais, Brazil</td>
<td></td>
</tr>
</tbody>
</table>

**Track 2: Cancer Cell Biology, Diagnostic and Prognostic Cancer Biomarkers**

Session Chair: Stephen J. Beebe, Old Dominion University, USA
Session Co-Chair: Sandip K. Mishra, Institute of Life Sciences, India

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35-10:55</td>
<td>Nanosecond pulsed electric fields abolish orthotopic rat hepatocellular carcinoma and bypass cancer mutations that evade apoptosis induction</td>
<td>Stephen J. Beebe, Old Dominion University, USA</td>
<td></td>
</tr>
<tr>
<td>10:55-11:15</td>
<td>Unraveling the story about the possible backups when estrogen receptor goes deregulated in breast cancer</td>
<td>Sandip K. Mishra, Institute of Life Science, Bhubaneswar, India</td>
<td></td>
</tr>
<tr>
<td>11:15-11:35</td>
<td>Identification of new molecular markers for minimal residual disease assessment in acute lymphocytic leukemia</td>
<td>Sona Pekova, Chambon, Laboratory for molecular diagnostics, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>11:35-11:55</td>
<td>Cell signaling and tissue dynamics of tumor initiation from suppressive epithelial environments</td>
<td>Cheuk T. Leung, University of Minnesota, USA</td>
<td></td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Cellular nanomechanics, a new drug sensitivity marker for ovarian cancer</td>
<td>Shivani Sharma, University of California, USA</td>
<td></td>
</tr>
<tr>
<td>12:15-12:35</td>
<td>The Warburg effect and beyond</td>
<td>Zhimin Lu, The University of Texas, MD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>12:35-12:55</td>
<td>Cancers and the Concept of Cell Senescence</td>
<td>Alvaro Macieira-Coelho, French National Institute of Health, France</td>
<td></td>
</tr>
</tbody>
</table>

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:55-14:15</td>
<td>Therapeutic efficacy of 131IRe-human serum albumin microsphere GP7TB hepatoma model via intraarterial route</td>
<td>Liang-Cheng Chen, Institute of Nuclear Energy Research, Taiwan</td>
<td></td>
</tr>
<tr>
<td>14:15-14:35</td>
<td>DMBA-Induced Mammary Tumor Obese Zucker Rat Model</td>
<td>Reza Hakak, University of Arkansas, USA</td>
<td></td>
</tr>
<tr>
<td>14:35-14:55</td>
<td>The etiology of bladder cancer and its dietary remedy</td>
<td>King-Thom Chung, The University of Memphis, USA</td>
<td></td>
</tr>
<tr>
<td>14:55-15:15</td>
<td>Psychoneuroendocrinology and cancer: Psychoimmunological evaluation and prognosis in cancer disease</td>
<td>Giuseppina Messina, University of L’Aquila, Italy</td>
<td></td>
</tr>
<tr>
<td>15:15-15:35</td>
<td>MDM2 modulates the cellular response to cdk4 inhibition</td>
<td>Andrew Koff, Memorial Sloan-Kettering Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>15:35-15:55</td>
<td>Asbestos cancer and biomarker HUNT</td>
<td>Oluf Dimitri Roe, Norwegian University of Science and Technology, Norway</td>
<td></td>
</tr>
<tr>
<td>15:55-16:15</td>
<td>Human cancer is a parasite spread via intrusion in genome</td>
<td>Sergey N. Rumyantsev, Andent, Inc., USA</td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break 16:15-16:30 @ Sierra Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-16:50</td>
<td>Cancer risk following CT-imaging: A Monte Carlo based study</td>
<td>Johann Wanek, University of Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>16:50-17:10</td>
<td>McAb NJO01 plays the key role of immunodiagnosis and immunotherapy for NSCLC</td>
<td>Shiyang Pan, Nanjing Medical University, China</td>
<td></td>
</tr>
<tr>
<td>17:10-17:30</td>
<td>Home Parenteral Nutrition in cancer and the suitability of prescription based on the duration of therapy</td>
<td>Michele Zanardi, ASLTO2 SAN Giovanni Bosco Hospital, Italy</td>
<td></td>
</tr>
<tr>
<td>17:30-17:50</td>
<td>Paraganglioma and SDH mutation</td>
<td>Fruhmann Johanna, Medical University Hospital Graz, Europe</td>
<td></td>
</tr>
<tr>
<td>17:50-18:10</td>
<td>Chronic low level arsenic may increase the risk of lung carcinogenesis: Role of inflammatory responses</td>
<td>Dona Sinha, Chittaranjan National Cancer Institute, India</td>
<td></td>
</tr>
<tr>
<td>18:10-18:30</td>
<td>Fractal and euclidean geometrical diagnosis of cervix cytology</td>
<td>Javier Rodriguez, Insight Group - Fundación universitaria de Ciencias de la Salud, Colombia</td>
<td></td>
</tr>
<tr>
<td>18:30-18:50</td>
<td>Fluorescence for diagnosis at point of care</td>
<td>Aurelijia Vaitkuviene, Lithuanian University, Lithuania</td>
<td></td>
</tr>
<tr>
<td>18:50-19:10</td>
<td>Mexican medicinal plants used for cancer treatment</td>
<td>Angel Josabad Alonso-Castro, National Autonomous University of Mexico, Mexico</td>
<td></td>
</tr>
<tr>
<td>19:10-19:30</td>
<td>Preclinical and clinical testing of a alpha-ketoglutarate/5-HMF/N-actyl-selenomethionine and N-acteyl-methionine for treating tumors</td>
<td>Joachim Greilberger, Medical University of Graz, Austria</td>
<td></td>
</tr>
</tbody>
</table>

19:30-20:30 Cocktails Sponsored by Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer
Day 2  October 22, 2013
Sierra Ballroom
Keynote Forum

08:30-08:55  Sudhakar Akul Yakkanti
Center for Cancer & Metabolism, Cell Signaling Laboratory, USA

08:55-09:20  Sherry A. Bradford
Accutheranostics Inc., USA

Workshop on “Animal models of cancer therapy”

09:00-09:35

Animal Models of Human Cancer Vaccines
Dorothy Herlyn, The Wistar Institute, USA

PHD2 silencing cooperates with BRafV600E to induce melanoma formation
Xiaowei Xu, University of Pennsylvania School of Medicine, USA

Mouse models as drivers in defining new targets for therapies - Examples from prostate cancer melanoma studies
Ze’ev Ronai, Sanford-Burnham Medical Research Institute, USA

Coffee Break 09:35-09:50 @ Sierra Foyer

10:00-10:25

Exploring The Response of BRAF or PIK3CA Mutated Cancers to Pathway-Targeted inhibition using Mouse models
Martin McMahon, University of California, USA

Patient derived xenograft models of melanoma as pre-clinical models for personalized medicine
Clemens Krepler, The Wistar Institute, USA

Hypoxia induces phenotypic plasticity in melanoma via the novel tyrosine kinase receptors ROR1 and ROR2
Michael O’Connell, The Wistar Institute, USA

Track 3: Organ-Specific Cancers, Cancer Genetics, Drug Development and Diagnostics

Session Chair: Michael Retsky, Harvard School of Public Health, USA
Session Co-Chair: Yoshiaki Omura, New York Medical College, USA

Session Introduction

Very high incidence of Carcinogenic Human Papilloma Virus Type 16 (HPV-16) was found with Chrysotile Asbestos, and HPV-18, with Tremolite Asbestos, was found in less than 10% in human breast cancer tissues: Their implications in diagnosis, treatment, and prevention of breast cancer
Yoshiaki Omura, New York Medical College, USA

Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: A population-based study
Ashrafi G. Hossein, Kingston University, UK

Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer
Michael J. Powell, DiaCarta, Inc., USA

Biological effects of therapeutic siRNA against TMPRSS2-ERG fusion oncogene for the treatment of prostate cancer
Michela Zanardi, ASLTO2 SAN Giovanni Bosco Hospital, Italy

The inhibition of breast cancer cell metastasis by anti-ErbB2 humanized antibody chA21 with a new recognition epitope
Guodong Shen, Anhui Provincial Hospital, China

Secretomic analysis reveals that alpha-actinin 4 induces cell migration and invasion and is a serological indicator of lung adenocarcinoma
Pao-Chi Liao, National Cheng Kung University, Taiwan

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:25

Prevalence and type distribution of high-risk human papillomavirus in patients with Cervical Cancer: A population-based study
Asrafi G. Hossein, Kingston University, UK

Cancer gene somatic mutation detection - A Tool for Personalized Cancer Therapy
Michael J. Powell, DiaCarta, Inc., USA

Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer
Michael J. Powell, DiaCarta, Inc., USA

Biological effects of therapeutic siRNA against TMPRSS2-ERG fusion oncogene for the treatment of prostate cancer
Michela Zanardi, ASLTO2 SAN Giovanni Bosco Hospital, Italy

The inhibition of breast cancer cell metastasis by anti-ErbB2 humanized antibody chA21 with a new recognition epitope
Guodong Shen, Anhui Provincial Hospital, China

Secretomic analysis reveals that alpha-actinin 4 induces cell migration and invasion and is a serological indicator of lung adenocarcinoma
Pao-Chi Liao, National Cheng Kung University, Taiwan

HPV Vaccination programs have not been demonstrated to be cost-effective in countries with comprehensive Pap screening and surgery
Judy Wilyman, University of Wollongong, Australia

Coffee Break 16:15-16:30 @ Sierra Foyer

16:30-16:50

Kazunaga Yui, The Apatone Development Center, USA

Nanodrug design and methods of activation for cancer therapy
Renato R. Letfullin, Rose-Hulman Institute of Technology, USA

Targeting microtubules in cancer Research: Application of computational simulations in developing novel chemotherapeutic agents
Andre Luis Branco de Barros, Federal University of Minas Gerais, Brazil

High preoperative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy
Wei Wang, Anhui Medical University, China

Therapeutic and diagnostic formulations for the treatment of skin and endoscopic accessible cancers
Jayakumar Rajadas, Stanford University School of Medicine, USA

Hyperdiploid tumors as a driving force in genomic instability
Roland B Sennerstam, Karolinska Hospital, Sweden

Diagnostic and prognostic value of UHRF1 in breast cancer patients
Feng Yan, Jiangsu Cancer Hospital & Nanjing Medical University Cancer Hospital, China
19:10-20:10  Cocktails Sponsored by Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer

Muir Woods

Track 3: Organ-Specific Cancers, Cancer Genetics, Drug Development and Diagnostics

Session Chair: Anupam Bishayee, American University of Health Sciences, USA
Session Co-Chair: James M. Jamison, Summa Health System, Saint Thomas Hospital, USA

11:35-11:55  Stromal androgen receptor in prostate cancer
Peng Lee, New York University Langone Medical Center, USA

11:55-12:15  The In Vitro, In Vivo and clinical activity of Apatone® against prostate cancer
James M. Jamison, Summa Health System, Saint Thomas Hospital, USA

12:15-12:35  Kaiso as prognosis marker of patients with Chronic myeloid leukemia
Jaime Coe, Santa Catarina University, Brazil

12:35-12:55  Cancer prevention and treatment by natural products: Current evidence and future opportunities
Anupam Bishayee, American University of Health Sciences, USA

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

Rita Isaac, Christian Medical College, India

14:15-14:35  Development of multi-pathway inhibitor screening system to combat the existing combinations of signaling dysregulations in gastric cancer
Kumaresan Ganesan, Madurai Kamaraj University, India

14:35-14:55  A cancer piggy-back screen to investigate whether changes in epigenetic state drive cancer growth
Harten SK, Queensland School of Medical Research, Australia

14:55-15:15  The role of integrated Positron Emission Tomography - Computed Tomography (PET-CT) imaging system in colorectal carcinoma
Abdul Jaiil Nordin, Universiti Putra Malaysia, Malaysia

15:15-15:35  Evaluation of anti-cancer activity of survivin siRNA delivered by polyethylene-glycol liposomes in k562-bearing xenograft
Suoqin Tang, Chinese PLA General Hospital, China

15:35-15:55  Dissecting molecular networks of leptin in breast cancer: Complexities and opportunities
Dipali Sharma, Sidney Kimmel Comprehensive Cancer Center, USA

Coffee Break 15:55-16:10 @ Sierra Foyer

16:10-17:30  Poster Presentations @ Monterey

18:50-19:50  Cocktails Sponsored by Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer

Day 3  October 23, 2013

Sierra Ballroom

Track 8: Tumor Science
Track 9: Novel Approaches to Cancer Therapeutics

Session Chair: Kun Ping Lu, Harvard Medical School, Boston, USA
Session Co-Chair: Porunelloor A. Mathew, University of North Texas Health Science Center, USA

09:00-09:20  A new etiology for Prostate cancer and BPH - The pelvic floor
Panikar Wadhera, Brooklyn hospital center, USA

09:20-09:40  Comparing the effectiveness of craniofacial and endoscopic surgical approaches for the treatment of ethmoidsinonasal tumors
Anisha R. Kumar, Stanford University School of Medicine, USA

09:40-10:00  Rosemary extract enhances 5-fluoracil antitumor effect and overcomes resistance to the drug: New complementary approach for colon cancer therapy
Ana Ramirez de Molina, IMDEA Food Institute, Spain

10:00-10:20  Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents
Bill E. Cham, Australasian Institute of Medical Research, Australia

10:20-10:40  Title:Moving Forward with an Immunotherapy for the Prevention of Breast Cancer Recurrence
Thomas Kieber-Emmons, University of Arkansas for Medical Sciences, USA

Coffee Break 10:40-10:55 @ Sierra Foyer

10:55-11:15  Natural killer cell receptors and targeted immunotherapy for cancer
Porunelloor A. Mathew, University of North Texas Health Science Center, USA

11:15-11:35  The unique proline isomerase Pin1: A novel drug target acting on numerous key cancer-driving pathways
Kun Ping Lu, Harvard Medical School, Boston, USA

11:35-11:55  Inflammatory events influencing the chemical induced-squamous cell carcinoma
Thais Helena Gasparoto, University of Sao Paulo, Brazil

11:55-12:15  Evaluation of anticancer effects of Avelos latex (Euphorbia tirucalli), across the tumor clones detection test (warts) in Drosophila melanogaster
Elcio Moreira Alves, University Center of Patos de Minas, Brazil

12:15-12:35  Molecular players of DNA damage response in human malignancies
Stefania Staibano, University of Naples Federico II, Italy

12:35-12:55  Significance of antigen receptors in the innate immunity of cancer cells
Gregory Lee, University of British Columbia, Canada

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15  Analysis of leukemic stem cell populations comparing NPM1wt and NPM1mut AML patients and potential therapeutic targets
Vanessa Schneider, University of Ulm, Germany

14:15-14:35  Inhibitors of the histone methylase EZH2, a new anti-tumoral therapy?
Catherine Bauge, Université de Caen Basse-Normandie, France

14:35-14:55  Hadrontherapy, a new hope against radio- and chimio-resistant tumors
Karim Boumediene, University of Caen, France
14:55-15:15  The risk of excessive vaccinations in the medullary thyroid Adenocarcinoma  
Manuela Stoicescu, University of Oradea, Romania

15:15-15:35  Hypoxic signature and cancer stem cell marker expression as tumor biology predictors  
Francesco Merolla, University “Federico II” of Naples, Italy

15:35-15:55  MiR-150 Contributes to the Proficiency of B-cell Receptor Signaling (BCR) in Malignant B cells  
Marek Mraz, Masaryk University, Czech Republic

Coffee Break 15:55-16:10 @ Sierra Foyer

16:10-16:30  Oncothermia-Nano-heating paradigm  
Oliver Szasz, St.Jarvins University, Hungary

16:30-16:50  NF-kB signaling in B-cell malignancies  
Sivakumar Vallabhapurapu, University of Cincinnati, USA

16:50-17:10  The role of centrosomal protein TAX1BP2 in the pathogenesis of hepatocellular carcinoma  
Yick-Pang Ching, The University of Hong Kong, SAR China

Muir Woods

Track 4: Carcinogenesis & Mutagenesis and OMICS in Cancer Research  
Track 6: Anti-Cancer Drug Discovery and Development

Session Chair: Samir A. Farghaly, The Weill Medical College of Cornell University, USA

Session Introduction

09:00-09:20  Factors that promote malignancy and factors that inhibit malignancy without side effects  
Yoshiaki Omura, New York Medical College, USA

09:20-09:40  Physical activity changes the reaction of circulating phagocytes to antineoplastic drug NSC631570  
Larysa Skivka, Taras Shevchenko National University of Kyiv, Ukraine

09:40-10:00  siRNA formulated with tumor targeting scfv modified iph nanoparticles as possible therapy for metastatic epithelial ovarian cancer  
Samir A. Farghaly, The Weill Medical College of Cornell University, USA

10:00-10:20  A novel genetic-based therapeutic platform for eradicating metastatic cancer  
Karli Rosner, Wayne State University, USA

10:20-10:40  Synthesis and anticancer screening studies of indole-based piperazine derivatives  
Mune Varin, Yeditepe University, Turkey

Coffee Break 10:40-10:55 @ Sierra Foyer

10:55-11:15  The antitumor effect of a polysaccharide from Strongylocentrotus nudus eggs (SEP) is mediated by stimulating cytotoxic lymphocytes in vivo  
Mengyun Ke, China Pharmaceutical University, PR China

11:15-11:35  Newcompounds of ruthenium present potential of treatment for cancer  
Elisangela de Paula Silveira Lacerda, Federal University of Goias, Brazil

11:35-11:55  Creating a new paradigm for cancer-based clinical trials by leveraging clinical and molecular data  
David A. Fenstermacher, Virginia Commonwealth University, USA

11:55-12:15  Synthesis and anticancer screening studies of benzhydrylpiperazine derivatives  
E. Ece Gurdal, Yeditepe University, Istanbul, Turkey

12:15-12:35  Measurement of DNA repair enzymes as cancer biomarkers  
Miral Dizdaroglu, National Institute of Standards and Technology, USA

12:35-12:55  Polyploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors  
Angus Harding, The Diamantina Institute, Australia

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15  Cancer - Could be cured?  
Jozef Oleksyszyn, Wroclaw University of Technology, Poland

14:15-14:35  Colloidal or silver nanoparticles reduce the growth of B16F10 melanoma tumors  
Franco-Molina M. A, Autonomous University of Nuevo Leon, Mexico

14:35-14:55  ONC1-138 - New effective antiandrogen for the treatment of prostate and breast cancer  
Ruben N. Karapetian, Chemical Diversity Research Institute, Russia

14:55-15:15  Phenethylisothiocyanate: A potential anti-cancer agent from watercress  
Ahmad Faizal Abdull Razis, Food Safety Research Centre (FOSREC), Malaysia

15:15-15:35  Effect of calcium ions on neuroblastoma differentiation  
Prithi Tiwari, Rutgers, The State University of New Jersey, USA

15:35-15:55  The anti-tumor activities of a type I ribosome-inactivating protein, trichosanthin, and its toxic mechanism on lymphoma cells  
O. Sha, University of Shenzhen, China

15:55-16:15  Development and characterization of transferrin modified artemether lipid nanospheres as a potent anticancer delivery system  
Eltayeb Suliman Elamin, China pharmaceutical university, China

Coffee Break 16:15-16:30 @ Sierra Foyer

Bookmark your dates  
4th World Congress on Cancer Science & Therapy  
October 20-22, 2014 Chicago, USA